← back to search

Qasim Bhorat

Centre for Advanced Study · AU
Area of research
Infectious Diseases · Health
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Vaccine Coverage and Hesitancy, and Diabetes Treatment and Management.
h-index
16
citations
9,680
works
30
NIH funding
primary concept
Medicine
email

Recent publications

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases 2024cited by 154position: middledoi
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
Clinical Infectious Diseases 2023cited by 52position: middledoi
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
Scientific Reports 2023cited by 48position: middledoi
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
Nature Immunology 2023cited by 32position: middledoi
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
Viruses 2023cited by 1position: middledoi
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
The Lancet HIV 2022cited by 66position: middledoi
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
New England Journal of Medicine 2021cited by 1,321position: middledoi
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
The Lancet 2021cited by 1,208position: middledoi
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
The Lancet HIV 2021cited by 159position: middledoi
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
The Lancet 2020cited by 5,000position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Keertan Dheda · London School of Hygiene & Tropical Medicine1 papers (2023–2023)Shabir A. Madhi · Washington University in St. Louis1 papers (2023–2023)Erica Lazarus · Jisc1 papers (2023–2023)Clare Cutland · International Federation of Gynaecology and Obstetrics1 papers (2023–2023)Andrew J. M. Nel · University of Cape Town1 papers (2023–2023)Jonathan M. Blackburn · University of Cape Town1 papers (2023–2023)Lee Fairlie · University College London1 papers (2023–2023) · 1 papers (2023–2023)Anthonet Koen · Anna Needs Neuroblastoma Answers1 papers (2023–2023)Gaurav Kwatra · Wellcome Centre for Infectious Diseases Research in Africa1 papers (2023–2023)Muneerah Smith · University of Cape Town1 papers (2023–2023)Carmen Briner · South African Medical Research Council1 papers (2023–2023)Alane Izu · AstraZeneca (Brazil)1 papers (2023–2023)Shaun Barnabas · Stellenbosch University1 papers (2023–2023)Vicky L. Baillie · National Research Foundation1 papers (2023–2023)